Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 16/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31608471 | 0.82 | HTR1A (0.43) | RBP4HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29961897 | 0.81 | SSTR4 (0.42) | RBP4HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16103507 | 0.78 | RBP4 (0.62) | RBP4 | |
| SCHEMBL30090937 | 0.78 | RBP4 (0.62) | RBP4 | |
| SCHEMBL29202377 | 0.77 | SCD (0.47) | RBP4 | |
| SCHEMBL20744282 | 0.74 | RBP4 (0.48) | RBP4 | |
| SCHEMBL30305350 | 0.74 | RBP4 (0.48) | RBP4 | |
| SCHEMBL17224411 | 0.73 | RBP4 (0.45) | RBP4 | |
| SCHEMBL29915616 | 0.73 | RBP4 (0.45) | RBP4 | |
| SCHEMBL6203314 | 0.72 | TSHR (0.45) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119630649-A | Nitrogen-containing saturated heterocyclic derivative | 住友制药株式会社 | 2025-03-14 | — | — | CN | claimed |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-18 | — | — | US | claimed |
| CN-119630649-A | Nitrogen-containing saturated heterocyclic derivative | 住友制药株式会社 | 2025-03-14 | — | — | CN | disclosed |
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-18 | — | — | US | disclosed |
| WO-2024024962-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC RING DERIVATIVE | 住友ファーマ株式会社 | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124429-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | RBP4 3913/4885HTR1A 98/4885SLC6A2 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.